Developing hypoxia and lactate metabolism-related molecular subtypes and prognostic signature for clear cell renal cell carcinoma through integrating machine learning DOI Creative Commons
Jinhui Liu, Tao Yang, Jiayuan Liu

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Nov. 13, 2024

The microenvironment of clear cell renal carcinoma (ccRCC) is characterized by hypoxia and increased lactate production. However, the impact metabolism on ccRCC remains incompletely understood. In this study, a new molecular subtype developed based hypoxia-related genes (HRGs) metabolism-related (LMRGs), aiming to create tool that can predict survival rate, immune status, responsiveness treatment patients. We obtained RNA-seq data clinical information patients with from TCGA GEO. HRGs LMRGs are sourced Molecular Signatures Database. Integrating 10 machine learning algorithms 101 frameworks, we constructed prognostic model related metabolism. Its accuracy reliability evaluated through constructing nomograms, drawing ROC curves, validating datasets. Additionally, risk subgroups functional enrichment, tumor mutational burden (TMB), infiltration degree, checkpoint expression level. Finally, evaluate immunotherapy determine personalized drugs for specific subgroups. 85 valuable were screened out. Functional enrichment analysis shows group high-risk scores (HLMRGS) mainly involved in activation immune-related activities, while low HLMRGS more active metabolic tumor-related pathways. At same time, differences cellular states between high observed. potential determined. have novel signature integrates It expected become an effective prognosis prediction, medicine ccRCC.

Language: Английский

Precision medicine in gynecological cancer (Review) DOI Open Access

Aikaterini Aravantinou‐Fatorou,

Vasiliki Georgakopoulou, Meletios Α. Dimopoulos

et al.

Biomedical Reports, Journal Year: 2025, Volume and Issue: 22(3)

Published: Jan. 8, 2025

The advent of personalized and precision medicine has revolutionized oncology treatment gynecological cancer. These innovative approaches tailor treatments to individual patient profiles beyond genetic markers considering environmental lifestyle factors, thereby optimizing therapeutic efficacy minimizing adverse effects. Precision uses advanced genomic technologies such as next‑generation sequencing perform comprehensive tumor profiling. This allows identification distinct mutations, expression patterns signaling pathway alterations, revealing the complex molecular landscape cancer ovarian, cervical uterine A major challenge in treating these cancers is their inherent heterogeneity, which can influence behavior, therapy response prognosis. aims overcome this by identifying biomarkers drivers for targeted selection. For example, breast (BRCA) gene mutations ovarian guided use poly (ADP‑ribose) polymerase inhibitors, leading more effective with fewer side Similar therapies immunotherapies have also been developed cancer, marking progress toward care. Future directions emphasize importance profiling development therapies. By understanding unique features each patient, clinicians select most strategies improve outcomes quality life.

Language: Английский

Citations

1
Exploring NUP62’s role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis DOI Creative Commons
Lihong Chen, Youfu He,

Menghui Duan

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 3, 2025

Background NUP62, a key component of the nuclear pore complex, is closely associated with cellular functions and cancer progression. However, its expression patterns, prognostic value, relationship tumour immunity drug sensitivity across multiple cancers have not been systematically studied. This study used multi-omics analyses combined experimental validation in gastric to investigate expression, functional characteristics, clinical relevance NUP62 cancer. Methods Data from TCGA, GTEx, CPTAC databases were analyse mutation associations NUP62. Tools such as SangerBox, TIMER 2.0, GSEA employed evaluate between immune microenvironment, well involvement signalling pathways. Immunohistochemistry RT-PCR validate tissues. PRISM CTRP utilised assess correlation sensitivity. Results was significantly upregulated poor prognosis clear cell renal carcinoma (KIRC), lower-grade glioma (LGG), adrenocortical (ACC), while playing protective role others, bladder (BLCA) stomach (STAD). Functional showed that involved cycle regulation, DNA damage repair, immunity. High correlated increased infiltration cells, macrophages T higher response rate immunotherapy. Drug analysis identified marker various chemotherapeutic agents. Validation experiments demonstrated mRNA protein levels tissues than adjacent normal Conclusions plays critical shows potential biomarker for diagnosis, prognosis, therapeutic prediction. Its pathways highlights target immunotherapy precision medicine.

Language: Английский

Citations

1
Comprehensive characterization of fatty acid oxidation in triple-negative breast cancer: Focus on biological roles and drug modulation DOI

Yunduo Liu,

Yanxia Zhang, Qin Xiang

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177343 - 177343

Published: Feb. 1, 2025

Language: Английский

Citations

0
The Pre-metastatic Niche: How Cancer Stem Cell-Derived Exosomal MicroRNA Fit into the Puzzle DOI

Behjat Kheiri Yeghaneh Azar,

Faezeh Vakhshiteh

Stem Cell Reviews and Reports, Journal Year: 2025, Volume and Issue: unknown

Published: March 17, 2025

Language: Английский

Citations

0
Targeting the tumour cell surface in advanced prostate cancer DOI
Cristina Boixareu,

Tarek Taha,

Varadha Balaji Venkadakrishnan

et al.

Nature Reviews Urology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
HSPA8 and HSPA9: Two prognostic and therapeutic targets in breast, colon, and kidney cancers? DOI
Alessia Ruzza,

Elisabetta Zaltron,

Federica Vianello

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167827 - 167827

Published: April 1, 2025

Language: Английский

Citations

0
Silencing PPP2R1A inhibits the progression of gastric cancer cells DOI Creative Commons
Guanghui Cheng,

Laibijiang Wusiman,

Dongfeng Song

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2025, Volume and Issue: 151(4)

Published: April 18, 2025

Abstract Background Protein phosphatase 2 regulatory subunit A alpha ( PPP2R1A ) is the most common scaffold protein in PP2A complex and has known tumor-suppressive functions. However, its role gastric cancer (GC) still unclear. This study aims to elucidate potential of biological functions GC. Methods The mutation status expression levels GC were assessed through bioinformatics analysis, correlation between patient survival rates was examined, functional network analyzed. Stable AGS MGC803 cell lines set up for overexpressing silencing . effects on proliferation, migration, invasion, apoptosis CCK-8 assays, scratch Transwell flow cytometry. Results significantly elevated samples P < 0.001) not caused by mutations > 0.05). Patients with high have a poorer 5-year rate 0.001). Silencing inhibits invasion cells while promoting 0.01). In contrast, overexpression does significant impact these cellular Conclusion oncogenic properties progression GC, knocking down can inhibit tumor cells. suggests that may serve as prognostic marker therapeutic target

Language: Английский

Citations

0
Perspectives on integrating artificial intelligence and single‐cell omics for cellular plasticity research DOI Open Access
Ahmed H. Ghobashi, Qin Ma

Quantitative Biology, Journal Year: 2025, Volume and Issue: 13(4)

Published: April 24, 2025

Abstract Cellular plasticity enables cells to dynamically adapt environmental changes by altering their phenotype. This plays a crucial role in tissue repair and regeneration contributes pathological processes such as cancer metastasis. Advances single‐cell omics have significantly advanced the study of cellular states provided new opportunities for accurate cell classification uncovering transitions. In this perspective, we emphasize integrating chromatin accessibility data extrinsic factors, microenvironmental cues, with transcriptomic develop holistic models identifying plastic states. Additionally, coupling artificial intelligence offers transformative potential address existing challenges fill gaps characterizing cells. We envision development universal metric, standardized metric quantifying plasticity. would enable consistent measurement across diverse studies, creating unified framework that bridges fields developmental biology, research, regenerative medicine. Fostering innovative approaches analyzing promises not only deepen our understanding but also accelerate therapeutic advancements, paving way novel precision medicine strategies treat complex diseases cancer.

Language: Английский

Citations

0
Dendritic cells pulsed with penetratin-OLFM4 inhibit the growth and metastasis of melanoma in mice DOI Creative Commons

Bum-Seo Baek,

Hyunmi Park, Ji‐Woong Choi

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 177, P. 117083 - 117083

Published: July 4, 2024

Cancer stem cells (CSCs) can self-renew and differentiate, contributing to tumor heterogeneity, metastasis, recurrence. Their resistance therapies, including immunotherapy, underscores the importance of targeting them for complete remission relapse prevention. Olfactomedin 4 (OLFM4), a marker associated with various cancers such as colorectal cancer, is expressed on CSCs promoting immune evasion tumorigenesis. However, its potential target CSC-specific immunotherapy remains underexplored. The primary aim this study evaluate effectiveness OLFM4 dendritic cell (DC)-based vaccines in inhibiting growth metastasis. To improve antigen delivery response, was conjugated protein-transduction domain (PTD) from antennapedia Drosophila called penetratin, creating fusion protein (P-OLFM4). efficacy DCs pulsed P-OLFM4 (DCs [P-OLFM4]) compared [OLFM4]) PBS [PBS]). [P-OLFM4] inhibited by 91.2 % significantly reduced lung metastasis OLFM4+ melanoma 97 %, [PBS]. [OLFM4] also demonstrated reduction 59.7 Immunization enhanced OLFM4-specific T-cell proliferation, interferon-γ production, cytotoxic T activity mice. results indicate that viable CSC-focused immunotherapy. DC elicit robust responses, This strategy holds promise developing more effective cancer treatments specifically CSCs, potentially leading better patient outcomes reducing likelihood

Language: Английский

Citations

3
Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials DOI Creative Commons
A.S. Serras, Célia Faustino, Lídia Pinheiro

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(8), P. 1047 - 1047

Published: Aug. 6, 2024

Cancer is still ranked among the top three causes of death in 30- to 69-year-old age group most countries and carries considerable societal macroeconomic costs that differ depending on cancer type, geography, patient gender. Despite advances several pharmacological approaches, lack stability specificity, dose-related toxicity, limited bioavailability chemotherapy (standard therapy) pose major obstacles treatment, with multidrug resistance being a driving factor failure. The past decades have been stage for intense research activity topic nanomedicine, which has resulted many nanotherapeutics reduced increased bioavailability, improved pharmacokinetics therapeutic efficacy employing smart drug delivery systems (SDDSs). Polymeric micelles (PMs) become an auspicious DDS medicinal compounds, used encapsulate hydrophobic drugs also exhibit substantial toxicity. Through preclinical animal testing, PMs pharmacokinetic profiles efficacy, resulting higher safety profile drugs. This review focuses are already clinical trials, traveling pathways from studies until introduction market.

Language: Английский

Citations

2